Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.11
LH's Cash to Debt is ranked lower than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. LH: 0.11 )
Ranked among companies with meaningful Cash to Debt only.
LH' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.08 Max: 0.59
Current: 0.11
0.02
0.59
Equity to Asset 0.34
LH's Equity to Asset is ranked lower than
80% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LH: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
LH' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.43 Max: 0.63
Current: 0.34
0.14
0.63
Interest Coverage 3.91
LH's Interest Coverage is ranked lower than
84% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. LH: 3.91 )
Ranked among companies with meaningful Interest Coverage only.
LH' s Interest Coverage Range Over the Past 10 Years
Min: 8.31  Med: 12.72 Max: 17.97
Current: 3.91
8.31
17.97
F-Score: 4
Z-Score: 1.96
M-Score: -2.13
WACC vs ROIC
6.75%
6.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.38
LH's Operating margin (%) is ranked higher than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. LH: 12.38 )
Ranked among companies with meaningful Operating margin (%) only.
LH' s Operating margin (%) Range Over the Past 10 Years
Min: 15.14  Med: 18.64 Max: 19.94
Current: 12.38
15.14
19.94
Net-margin (%) 5.59
LH's Net-margin (%) is ranked higher than
70% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. LH: 5.59 )
Ranked among companies with meaningful Net-margin (%) only.
LH' s Net-margin (%) Range Over the Past 10 Years
Min: 8.5  Med: 10.74 Max: 12.02
Current: 5.59
8.5
12.02
ROE (%) 11.15
LH's ROE (%) is ranked higher than
78% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. LH: 11.15 )
Ranked among companies with meaningful ROE (%) only.
LH' s ROE (%) Range Over the Past 10 Years
Min: 19.25  Med: 22.35 Max: 28.64
Current: 11.15
19.25
28.64
ROA (%) 3.83
LH's ROA (%) is ranked higher than
66% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. LH: 3.83 )
Ranked among companies with meaningful ROA (%) only.
LH' s ROA (%) Range Over the Past 10 Years
Min: 7.17  Med: 10.21 Max: 11.43
Current: 3.83
7.17
11.43
ROC (Joel Greenblatt) (%) 48.25
LH's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. LH: 48.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 78.64  Med: 110.13 Max: 138.05
Current: 48.25
78.64
138.05
Revenue Growth (3Y)(%) 8.50
LH's Revenue Growth (3Y)(%) is ranked higher than
66% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. LH: 8.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.4  Med: 10.20 Max: 20
Current: 8.5
-21.4
20
EBITDA Growth (3Y)(%) 5.50
LH's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. LH: 5.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.3  Med: 10.35 Max: 17.6
Current: 5.5
-8.3
17.6
EPS Growth (3Y)(%) 5.00
LH's EPS Growth (3Y)(%) is ranked higher than
57% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. LH: 5.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 5  Med: 15.35 Max: 82.8
Current: 5
5
82.8
» LH's 10-Y Financials

Financials (Next Earnings Date: 2016-02-18)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

LH Guru Trades in Q1 2015

John Hussman 90,000 sh (New)
John Keeley 10,760 sh (New)
Caxton Associates 3,000 sh (New)
Ray Dalio 96,536 sh (+37.84%)
Mario Gabelli 5,000 sh (+25.00%)
John Rogers 1,404,802 sh (+1.31%)
First Pacific Advisors 50,400 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Charles Brandes Sold Out
Scott Black 73,891 sh (-0.22%)
Jeff Auxier 4,180 sh (-8.73%)
Richard Pzena 728,078 sh (-12.35%)
Paul Tudor Jones 10,793 sh (-21.25%)
Chris Davis 4,443,459 sh (-25.05%)
Wallace Weitz 746,258 sh (-25.12%)
Jeremy Grantham 39,680 sh (-56.48%)
Jim Simons 250,605 sh (-58.03%)
Joel Greenblatt 104,024 sh (-63.43%)
» More
Q2 2015

LH Guru Trades in Q2 2015

Larry Robbins 3,983,595 sh (New)
Louis Moore Bacon 10,027 sh (New)
David Dreman 5,976 sh (New)
John Keeley 20,600 sh (+91.45%)
Jeremy Grantham 66,780 sh (+68.30%)
Mario Gabelli 6,000 sh (+20.00%)
Scott Black 80,011 sh (+8.28%)
John Rogers 1,501,141 sh (+6.86%)
Jeff Auxier 4,305 sh (+2.99%)
John Hussman 90,000 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
Caxton Associates Sold Out
Richard Pzena 719,376 sh (-1.20%)
Wallace Weitz 720,849 sh (-3.40%)
Chris Davis 4,215,809 sh (-5.12%)
Joel Greenblatt 80,999 sh (-22.13%)
Jim Simons 191,605 sh (-23.54%)
Paul Tudor Jones 6,200 sh (-42.56%)
Ray Dalio 39,991 sh (-58.57%)
» More
Q3 2015

LH Guru Trades in Q3 2015

Pioneer Investments 7,744 sh (New)
Andreas Halvorsen 5,053,349 sh (New)
Ray Dalio 56,011 sh (+40.06%)
Larry Robbins 4,865,795 sh (+22.15%)
John Rogers 1,627,421 sh (+8.41%)
Wallace Weitz 735,729 sh (+2.06%)
John Hussman 90,000 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Jeff Auxier 4,180 sh (-2.90%)
Mario Gabelli 5,600 sh (-6.67%)
Scott Black 73,916 sh (-7.62%)
John Keeley 18,925 sh (-8.13%)
Jeremy Grantham 50,190 sh (-24.84%)
Chris Davis 2,036,449 sh (-51.69%)
Joel Greenblatt 33,765 sh (-58.31%)
Richard Pzena 273,766 sh (-61.94%)
Jim Simons 68,405 sh (-64.30%)
David Dreman 486 sh (-91.87%)
» More
Q4 2015

LH Guru Trades in Q4 2015

Mario Gabelli 5,600 sh (unchged)
John Hussman Sold Out
Jeff Auxier 3,330 sh (-20.33%)
Richard Pzena 17,560 sh (-93.59%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Laboratory Corp of America Hldgs

Weitz Funds Comments on Laboratory Corporation of America Holdings - Feb 01, 2016

Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations.



From Weitz Funds' Balanced Fund fourth quarter 2015 commentary.



Check out Wallace Weitz latest stock trades

John Rogers Comments on Laboratory Corp. of America Holdings - May 07, 2014

We purchased a previous holding in our mid ca p fund, Laboratory Corp. of America Holdings (LH). LabCorp maintains a leading market position in an indust ry that continues to show promising growth potential du e to technological advances, aging demographics, health care cost containment, and preventative medicine. LabCorp maintains a solid balance sheet, generates a significant amount of free cash flow and has been returning value to shareholders through share repurchases. The company operates with an experienced management team that is conservative yet willing to take slight risks in order to grow the business long-term.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Laboratory Corp of America Hldgs

Weitz Funds Comments on Laboratory Corporation of America Holdings Guru stock highlight
Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations. Read more...
Halvorsen's Investment Makes Broadcom His 5th-Most Valuable Stake Health care-oriented guru acquires stake in Netflix in 3rd quarter
Health care stocks have the highest weighting – 30% – in Andreas Halvorsen (Trades, Portfolio)’s portfolio so it shouldn’t be a surprise that many of his largest transactions in the third quarter involved health care-related stocks, but his largest deal of the quarter belongs more properly to the second-highest weighted sector in his portfolio, Technology. Read more...
Andreas Halvorsen Buys Stake in Laboratory Corp. of America Holdings Guru acquires more than 5 million shares of health care network operator
Andreas Halvorsen (Trades, Portfolio) of Viking Global Investors LP bought a stake in Laboratory Corp. of America Hldgs. (NYSE:LH) on Oct. 1. Read more...
John Hussman Increases Portfolio in 1Q2015
John Hussman (Trades, Portfolio) is known for his negative thoughts on the Federal Reserve and the U.S. Treasury. He has been named the "Prophet of Doom" because he predicted the financial crisis of 2008 and says there is another to come that will be much worse. Read more...
Westport Buys Apparel Retailer Express During Q4
Andrew J. Knuth founded Westport Asset Management (Trades, Portfolio) in 1983 with a focus on investing in small-cap companies for institutional clients. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.60
LH's P/E(ttm) is ranked higher than
72% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.91 vs. LH: 22.60 )
Ranked among companies with meaningful P/E(ttm) only.
LH' s P/E(ttm) Range Over the Past 10 Years
Min: 12.98  Med: 17.21 Max: 27.54
Current: 22.6
12.98
27.54
Forward P/E 10.47
LH's Forward P/E is ranked higher than
91% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.38 vs. LH: 10.47 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.68
LH's PE(NRI) is ranked higher than
71% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. LH: 22.68 )
Ranked among companies with meaningful PE(NRI) only.
LH' s PE(NRI) Range Over the Past 10 Years
Min: 12.97  Med: 17.22 Max: 27.6
Current: 22.68
12.97
27.6
P/B 2.11
LH's P/B is ranked higher than
60% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. LH: 2.11 )
Ranked among companies with meaningful P/B only.
LH' s P/B Range Over the Past 10 Years
Min: 2.09  Med: 3.50 Max: 5.19
Current: 2.11
2.09
5.19
P/S 1.24
LH's P/S is ranked higher than
74% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. LH: 1.24 )
Ranked among companies with meaningful P/S only.
LH' s P/S Range Over the Past 10 Years
Min: 1.23  Med: 1.68 Max: 2.97
Current: 1.24
1.23
2.97
PFCF 17.10
LH's PFCF is ranked higher than
82% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.13 vs. LH: 17.10 )
Ranked among companies with meaningful PFCF only.
LH' s PFCF Range Over the Past 10 Years
Min: 9.15  Med: 14.98 Max: 32.44
Current: 17.1
9.15
32.44
POCF 12.49
LH's POCF is ranked higher than
79% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.16 vs. LH: 12.49 )
Ranked among companies with meaningful POCF only.
LH' s POCF Range Over the Past 10 Years
Min: 7.45  Med: 11.43 Max: 21.26
Current: 12.49
7.45
21.26
EV-to-EBIT 16.61
LH's EV-to-EBIT is ranked higher than
62% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.49 vs. LH: 16.61 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 11.60 Max: 21.5
Current: 16.61
8.7
21.5
EV-to-EBITDA 11.74
LH's EV-to-EBITDA is ranked higher than
67% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.68 vs. LH: 11.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
LH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 9.50 Max: 16.1
Current: 11.74
7.2
16.1
PEG 3.98
LH's PEG is ranked lower than
67% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.69 vs. LH: 3.98 )
Ranked among companies with meaningful PEG only.
LH' s PEG Range Over the Past 10 Years
Min: 0.83  Med: 1.49 Max: 5.67
Current: 3.98
0.83
5.67
Shiller P/E 19.70
LH's Shiller P/E is ranked higher than
84% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. LH: 19.70 )
Ranked among companies with meaningful Shiller P/E only.
LH' s Shiller P/E Range Over the Past 10 Years
Min: 18.84  Med: 23.86 Max: 75.2
Current: 19.7
18.84
75.2
Current Ratio 1.47
LH's Current Ratio is ranked lower than
76% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. LH: 1.47 )
Ranked among companies with meaningful Current Ratio only.
LH' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.64 Max: 3.64
Current: 1.47
0.47
3.64
Quick Ratio 1.37
LH's Quick Ratio is ranked lower than
72% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. LH: 1.37 )
Ranked among companies with meaningful Quick Ratio only.
LH' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.52 Max: 3.45
Current: 1.37
0.44
3.45
Days Inventory 11.60
LH's Days Inventory is ranked higher than
92% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. LH: 11.60 )
Ranked among companies with meaningful Days Inventory only.
LH' s Days Inventory Range Over the Past 10 Years
Min: 11.89  Med: 12.26 Max: 13.25
Current: 11.6
11.89
13.25
Days Sales Outstanding 57.13
LH's Days Sales Outstanding is ranked higher than
59% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. LH: 57.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.64  Med: 49.42 Max: 55.91
Current: 57.13
44.64
55.91
Days Payable 31.16
LH's Days Payable is ranked lower than
77% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. LH: 31.16 )
Ranked among companies with meaningful Days Payable only.
LH' s Days Payable Range Over the Past 10 Years
Min: 20.61  Med: 24.91 Max: 32.38
Current: 31.16
20.61
32.38

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.85
LH's Price/Projected FCF is ranked higher than
89% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.03 vs. LH: 0.85 )
Ranked among companies with meaningful Price/Projected FCF only.
LH' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.68  Med: 1.03 Max: 6.11
Current: 0.85
0.68
6.11
Price/DCF (Earnings Based) 1.55
LH's Price/DCF (Earnings Based) is ranked higher than
71% of the 28 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.78 vs. LH: 1.55 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.75
LH's Price/Median PS Value is ranked higher than
70% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. LH: 0.75 )
Ranked among companies with meaningful Price/Median PS Value only.
LH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.96 Max: 1.78
Current: 0.75
0.07
1.78
Earnings Yield (Greenblatt) (%) 6.05
LH's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. LH: 6.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 8.60 Max: 11.4
Current: 6.05
4.7
11.4
Forward Rate of Return (Yacktman) (%) 11.03
LH's Forward Rate of Return (Yacktman) (%) is ranked higher than
51% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. LH: 11.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LH' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 10.1  Med: 18.40 Max: 23.2
Current: 11.03
10.1
23.2

More Statistics

Revenue(Mil) $7892
EPS $ 4.53
Beta0.81
Short Percentage of Float3.46%
52-Week Range $97.79 - 131.19
Shares Outstanding(Mil)101.20

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 8,443 9,044 9,531
EPS($) 7.53 8.53 9.64
EPS without NRI($) 7.53 8.53 9.64

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ALR, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:LAB.Germany,
Laboratory Corp of America Hldgs, founded in 1971, is an independent clinical laboratory company in the United States. Since the Company's founding, it has grown into a national network of 39 primary laboratories and over 1,750 patient service centers along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately). Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. The Company believes that it competes favorably with its principal competitors in each of these areas and is currently implementing strategies designed to improve its competitive position. The Company's strategic plan continues to focus on three critical priorities: scientific differentiation, managed care, and customer service. The Company offers its services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Primary Care, Obstetrics-Gynecology, Specialty Medicine (e.g., Infectious Disease, Endocrinology, Gastroenterology and Rheumatology), Oncology and Hospitals. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
» More Articles for LH

Headlines

Articles On GuruFocus.com
Weitz Funds Comments on Laboratory Corporation of America Holdings Feb 01 2016 
Guru, Philanthropist Larry Robbins Adds to 3 Healthcare-Related Holdings Dec 06 2015 
Halvorsen's Investment Makes Broadcom His Fifth-Most Valuable Stake Dec 05 2015 
Andreas Halvorsen Buys Stake in Laboratory Corp. of America Holdings Oct 14 2015 
Eight Bridges Capital Management's July 2015 Investor Letter Sep 01 2015 
John Hussman's Top Five New Buys in the First Quarter May 12 2015 
John Hussman Increases Portfolio in 1Q2015 May 04 2015 
Laboratory Corporation of America Holdings Q4 Earnings Beat Market Expectations Feb 24 2015 
Westport Buys Apparel Retailer Express During Q4 Feb 11 2015 
Investment Ideas from Guy Spier - Part 2 Jan 07 2015 

More From Other Websites
LabCorp and Cheeriodicals Spread Cheer to UNC Children’s Jan 27 2016
Are Insiders Selling These 3 High-Potential Stocks Too Early? Jan 13 2016
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jan 13 2016
Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp Jan 12 2016
Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp Jan 12 2016
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Change in Directors or Principal Officers Jan 07 2016
LabCorp Announces New Board Member Jan 07 2016
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jan 06 2016
Laboratory Corp. of America Holdings breached its 50 day moving average in a Bearish Manner :... Jan 06 2016
LabCorp is Scheduled to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 06 2016
LabCorp Poised on Strategic Initiatives, Currency Woes Linger Jan 05 2016
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jan 05 2016
Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease... Jan 04 2016
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jan 04 2016
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Jan 04 2016
LabCorp hit with penalty after allegations it skirted lab testing law in New York Dec 31 2015
Healthcare's Latest Prognosis Dec 25 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Change in Directors or Principal Officers Dec 18 2015
Laboratory Corp. of America Holdings – Value Analysis (NYSE:LH) : December 16, 2015 Dec 16 2015
Laboratory Corp. of America Holdings breached its 50 day moving average in a Bearish Manner :... Dec 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK